银屑病药物专题报告:生物制剂和口服药物百花齐放 银屑病治疗未来可期

华鑫证券
Sep 09

银屑病目前不能治愈,治疗需求庞大,药物市场空间广阔银屑病是一种慢性、复发性、炎症性和系统性皮肤病,全球约有1.25亿银屑病患者,中国约有670万人。其中,20%至30%的患者患有中重度银屑病。银屑病现阶段还无法彻底治愈,需要长期治疗以控制病情,治疗需求庞大。现有治疗方案包括外用药物、物理治疗、系统治疗和生物制剂。根据数据统计,全球银屑病治疗市场2022年规模为265亿美元。中国银屑病药物市场近年来...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10